Department of Obstetrics and Gynecology, The Warren Alpert Medical School, Brown University, Providence, RI, United States; Women & Infants' Hospital Program in Women's Oncology, Providence, RI, United States.
Gynecology Oncology, Duke Cancer Institute, Durham, NC, United States; The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Durham, NC, United States.
Cancer Treat Rev. 2018 Sep;69:53-65. doi: 10.1016/j.ctrv.2018.06.001. Epub 2018 Jun 5.
Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology community has begun to shift its focus to molecular targeted agents, alternative dosing schedules, and maintenance therapy. Women who achieve a response to initial adjuvant chemotherapy may be candidates for maintenance therapy, with the goal of inducing a lasting remission or prolonging the disease-free interval before recurrence. The rationale for maintenance therapy is to delay disease progression by eliminating residual, slowly-dying cancerous cells, or impeding cell turnover. This review discusses the goals of maintenance therapy for EOC with antiangiogenic agents or poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and reviews clinical studies that have demonstrated improvements in survival outcomes. The side-effect profiles for PARP inhibitors and the implications for preserving quality of life during maintenance therapy will also be discussed.
大约 1%的美国女性在其一生中会被诊断患有上皮性卵巢癌（EOC）。EOC 通常在更晚期才被发现，需要采取积极的治疗措施，而且大多数女性会因此病而死亡。由于治疗方法的进步，肿瘤学界已开始将重点转向分子靶向药物、替代剂量方案和维持治疗。对初始辅助化疗有反应的女性可能是维持治疗的候选者，其目标是诱导持久缓解或在复发前延长无病间期。维持治疗的基本原理是通过消除残留的、缓慢死亡的癌细胞或阻碍细胞更替来延缓疾病进展。本综述讨论了用抗血管生成药物或聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂进行 EOC 维持治疗的目标，并回顾了显示生存结果改善的临床研究。还将讨论 PARP 抑制剂的副作用概况以及在维持治疗期间对生活质量的影响。
